| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IHPK3 |
| Uniprot No | Q96PC2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-410aa |
| 氨基酸序列 | MVVQNSADAG DMRAGVQLEP FLHQVGGHMS VMKYDEHTVC KPLVSREQRF YESLPLAMKR FTPQYKGTVT VHLWKDSTGH LSLVANPVKE SQEPFKVSTE SAAVAIWQTL QQTTGSNGSD CTLAQWPHAQ LARSPKESPA KALLRSEPHL NTPAFSLVED TNGNQVERKS FNPWGLQCHQ AHLTRLCSEY PENKRHRFLL LENVVSQYTH PCVLDLKMGT RQHGDDASEE KKARHMRKCA QSTSACLGVR ICGMQVYQTD KKYFLCKDKY YGRKLSVEGF RQALYQFLHN GSHLRRELLE PILHQLRALL SVIRSQSSYR FYSSSLLVIY DGQEPPERAP GSPHPHEAPQ AAHGSSPGGL TKVDIRMIDF AHTTYKGYWN EHTTYDGPDP GYIFGLENLI RILQDIQEGE |
| 预测分子量 | 46,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3条关于IHPK3重组蛋白的参考文献示例(内容为虚构，供格式参考)：
1. **标题**: *Recombinant Expression and Enzymatic Characterization of Human Inositol Hexakisphosphate Kinase 3 (IP6K3)*
**作者**: Smith, J.R.; Lee, H.; Chen, W.
**摘要**: 本研究通过大肠杆菌系统成功表达了带有His标签的重组人源IP6K3蛋白，并优化了纯化条件。酶活分析表明，该蛋白对IP6的磷酸化活性依赖于ATP，且受镁离子浓度调控。研究为后续IP6K3的生化功能研究提供了工具。
2. **标题**: *Structural Insights into IP6K3 Catalytic Mechanism via X-ray Crystallography*
**作者**: Gupta, S.; Park, S.Y.; Kim, D.
**摘要**: 通过X射线晶体学解析了重组IP6K3蛋白的2.8Å分辨率结构，揭示了其ATP结合域的关键氨基酸残基及底物结合口袋的构象变化，阐明了IP6K3催化IP6生成5-IP7的分子机制。
3. **标题**: *IP6K3 Recombinant Protein Modulates Cellular Apoptosis in Cancer Models*
**作者**: Zhang, L.; Wang, Q.; Rossi, M.
**摘要**: 利用哺乳动物细胞表达系统制备功能性IP6K3重组蛋白，体外实验证实其过表达可抑制癌细胞凋亡，并发现该效应与5-IP7介导的AKT信号通路激活相关，提示IP6K3作为潜在肿瘤治疗靶点。
注：以上文献为模拟示例，实际研究请参考真实数据库(如PubMed)或结合具体课题调整。
**Background of IHPK3 Recombinant Protein**
IHPK3 (Inositol Hexakisphosphate Kinase 3) is a member of the inositol phosphate kinase family, which plays a critical role in regulating cellular signaling pathways by phosphorylating inositol phosphates. Specifically, IHPK3 catalyzes the conversion of inositol hexakisphosphate (IP6) to inositol heptakisphosphate (IP7), a high-energy signaling molecule involved in diverse processes such as gene expression, vesicle trafficking, and apoptosis. Dysregulation of IP7 levels has been linked to pathologies, including cancer, neurodegenerative disorders, and metabolic diseases, highlighting the therapeutic and research relevance of IHPK3.
Recombinant IHPK3 protein is produced through genetic engineering, typically by expressing the *IP6K3* gene in bacterial or mammalian systems. This allows large-scale production of purified, functional protein for *in vitro* studies. The recombinant form retains enzymatic activity, enabling researchers to investigate its biochemical properties, substrate specificity, and interactions with inhibitors or cofactors.
Studies using IHPK3 recombinant protein have shed light on its role in cellular energy sensing, as IP7 modulates AMP-activated protein kinase (AMPK) activity, a master regulator of metabolism. Additionally, IHPK3 has been implicated in immune responses, with evidence suggesting its involvement in T-cell signaling and inflammation. Its potential as a drug target is under exploration, particularly in cancers where IP7 dysregulation promotes proliferation or resistance to therapy.
Overall, IHPK3 recombinant protein serves as a vital tool for dissecting the complexity of inositol phosphate signaling and developing targeted therapies for diseases linked to its dysfunction. Ongoing research aims to clarify its tissue-specific functions and validate its clinical applicability.
×
